AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Agenus shares surge 11.21% intraday after reporting Q3 clinical advances and France regulatory approvals.
ByAinvest
Monday, Nov 10, 2025 12:57 pm ET1min read
Agenus Inc. surged 11.21% intraday following the release of Q3 2025 results highlighting clinical and regulatory advancements. The company announced reimbursed compassionate access for its botensilimab/balstilimab (BOT/BAL) combination in France for refractory metastatic colorectal cancer, marking the first government-funded access for this patient population. Updated clinical data showed 42% two-year survival in MSS mCRC patients and 39% across multiple cancers, reinforcing BOT/BAL’s potential. Additionally, the global Phase 3 BATTMAN trial is set to launch in Q4 2025, signaling regulatory progress. Financially, a $100.9 million gain from the deconsolidation of MiNK Therapeutics and a $10 million bridge facility with Zydus contributed to a $63.9 million net income, contrasting with prior losses. These developments, emphasizing therapeutic efficacy, expanded access, and financial improvement, drove the intraday rally.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet